November 21, 2017 8:54 PM ET

Life Sciences Tools and Services

Company Overview of Catalent Pharma Solutions, Inc.

Company Overview

Catalent Pharma Solutions, Inc. provides development solutions and delivery technologies for drugs, biologics, and consumer health products. The company’s Development and Clinical Services segment offers manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. This segment also provides analytical chemical and cell-based testing and scientific services; respiratory products formulation and manufacturing; regulatory consulting; and bioanalytical testing for biologic products. Its Oral Technologies segment offers oral delivery technologies, including formulation, development, and manufacturing services for the oral dose forms comprising p...

14 Schoolhouse Road

Somerset, NJ 08873

United States

8,300 Employees

Phone:

732-537-6200

Fax:

732-537-6480

Key Executives for Catalent Pharma Solutions, Inc.

Chair, CEO & President
Age: 53
Executive VP, CFO & Principal Accounting Officer
Age: 50
President of Advanced Delivery Technologies
Age: 51
President of Catalent Asia Pacific
President of Softgel Technologies
Age: 51
Compensation as of Fiscal Year 2017.

Catalent Pharma Solutions, Inc. Key Developments

Catalent Pharma Solutions, Inc. Announces Pricing of Private Offering of Senior Unsecured Notes Due 2026

Catalent Pharma Solutions, Inc. priced a private offering of $450.0 million in aggregate principal amount of 4.875% senior unsecured notes due 2026 at par. The operating subsidiary intends to use the net proceeds from the private offering to fund, in part, the purchase price of the previously announced pending acquisition of Cook Pharmica LLC. The company expects to fund the balance of the purchase price due at the closing of the acquisition and pay related fees and expenses with the net proceeds from the previously announced underwritten public offering of its common stock, which closed on September 29, 2017, of $277.4 million as well as cash on hand. The closing of the private offering is not contingent upon the closing of the acquisition. If for any reason the acquisition is not consummated on or prior to March 18, 2018, the acquisition agreement is terminated prior to March 18, 2018, or the operating subsidiary notifies the trustee in writing that it will not pursue the consummation of the acquisition or otherwise publicly announces that the acquisition will not be consummated, then the operating subsidiary will be required to redeem all of the outstanding notes for cash at a redemption price equal to 100% of the issue price of the notes, plus accrued and unpaid interest to, but excluding, the redemption date. The proceeds from the private offering will not be deposited into an escrow account or otherwise segregated from the general funds of the operating subsidiary pending the closing of the acquisition or any such redemption. The notes will be guaranteed by all of the wholly owned U.S. subsidiaries of the operating subsidiary that guarantee its senior secured credit facilities. The notes will not be guaranteed by PTS Intermediate Holdings LLC or the company, the direct and indirect parent companies of the operating subsidiary. The private offering is exempt from the registration requirements of the Securities Act of 1933, as amended. The notes will be offered and sold to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and to certain non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act.

Catalent Pharma Solutions, Inc. Intends to Offer $450 Million in Aggregate Principal Amount of Senior Unsecured Notes Due 2026

Catalent, Inc. announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the operating subsidiary), intends to offer, subject to market and other conditions, $450 million in aggregate principal amount of senior unsecured notes due 2026 in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended. The Operating Subsidiary intends to use the net proceeds from the Private Offering to fund, in part, the purchase price of the previously announced pending acquisition of Cook Pharmica LLC. Catalent expects to fund the balance of the purchase price and pay related fees and expenses with $277.4 million of the approximate net proceeds from the previously announced underwritten public offering of its common stock, which closed on September 29, 2017, as well as cash on hand. The closing of the Private Offering is not contingent upon the closing of the Acquisition. If for any reason the Acquisition is not consummated on or prior to March 18, 2018, the Acquisition Agreement is terminated prior to March 18, 2018, or the Operating Subsidiary notifies the trustee in writing that it will not pursue the consummation of the Acquisition or otherwise publicly announces that the Acquisition will not be consummated, then the Operating Subsidiary will be required to redeem all of the outstanding Notes for cash at a redemption price equal to 100% of the issue price of the Notes, plus accrued and unpaid interest to, but excluding, the redemption date. The Notes will be guaranteed by all of the wholly owned U.S. subsidiaries of the Operating Subsidiary that guarantee its senior secured credit facilities. The Notes will not be guaranteed by PTS Intermediate Holdings, LLC or Catalent, the direct and indirect parent companies of the Operating Subsidiary. The Notes will be offered and sold to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and to certain non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act.

Therapix Biosciences Ltd. Enters into an Exclusive Agreement with Catalent Pharma Solutions for the Formulation, Development and Clinical Manufacturing of THX-TS01

Therapix Biosciences Ltd. announced that it has entered into an exclusive agreement with Catalent Pharma Solutions, for the formulation, development and clinical manufacturing of THX-TS01, a first-in-class, proprietary investigational drug candidate for the treatment of the symptoms of Tourette Syndrome. Pursuant to the agreement, Catalent will develop THX-TS01 in softgel form in support of Therapix's clinical development program and in accordance with current good manufacturing practice (cGMP). The formulation, development, analytical and cGMP manufacturing activities will be conducted at Catalent's primary softgel development and manufacturing facility in St. Petersburg, Florida. THX-TS01 is a combination drug candidate for the treatment of the symptoms of Tourette Syndrome and it is based on two components: dronabinol, the active ingredient in an FDA approved synthetic analog of tetrahydrocannabinol, which is the psychoactive molecule in the cannabis plant, and palmitoylethanolamide, which is an endogenous fatty acid amide that belongs to the class of nuclear factor agonists, which are proteins that regulate the expression of genes. The combination of THC and PEA may induce a reaction known as the "entourage effect". The basic tenet of the entourage effect is that cannabinoids work together, or possess synergy, and affect the body in a mechanism similar to the body's own endocannabinoid system, which is a group of molecules and receptors in the brain that mediates the psychoactive effects of cannabis. This entourage effect may account for the pharmacological actions of PEA. Based on an activity enhancement of other physiological compounds, PEA may indirectly stimulate the cannabinoid receptors by potentiating their affinity for a receptor or by inhibiting their metabolic degradation, and by doing so, may increase the uptake of cannabinoid compounds, such as THC. Thus, it is speculated that the presence of the PEA molecule likely increases the efficacy of orally administered THC, while reducing the required dosage and decreasing associated deleterious adverse events.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 19, 2017
Cook Pharmica LLC
Merger/Acquisition
November 28, 2016
Accucaps Industries Limited
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Catalent Pharma Solutions, Inc., please visit www.catalent.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.